Pazopanib
| Evidence Level: L5 | Predicted Indications: 51 |
Quick Overview
| Item | Value |
|---|---|
| Drug Name | Pazopanib |
| DrugBank ID | DB06589 |
| Brand Names (EU) | Votrient |
| Evidence Level | L5 |
| Predicted Indications | 51 |
| Top Prediction Score | 99.78% |
Approved Indication (EMA)
Renal-cell carcinoma (RCC) Votrient is indicated in adults for the first-line treatment of advanced renal-cell carcinoma (RCC) and for patients who have received prior cytokine therapy for advanced disease. Soft-tissue sarcoma (STS) Votrient is indicated for the treatment of adult patients with selective subtypes of advanced soft-tissue sarcoma (STS) who have received prior chemotherapy for metastatic disease or who have progressed within 12 months after (neo)adjuvant therapy. Efficacy and safet
Predicted New Indications
TxGNN model predictions for potential drug repurposing:
| Rank | Indication | Score | Source |
|---|---|---|---|
| 1 | clear cell renal carcinoma | 99.78% | DL |
| 2 | renal cell carcinoma associated with Xp11.2 translocations/TFE3 gene fusions | 99.63% | DL |
| 3 | unclassified renal cell carcinoma | 99.63% | DL |
| 4 | renal cell carcinoma associated with neuroblastoma | 99.63% | DL |
| 5 | liposarcoma | 99.59% | DL |
| 6 | childhood kidney cell carcinoma | 99.54% | DL |
| 7 | ovarian myxoid liposarcoma | 99.51% | DL |
| 8 | heart fibrosarcoma | 99.37% | DL |
| 9 | fibroblastic neoplasm | 99.35% | DL |
| 10 | kidney fibrosarcoma | 99.33% | DL |
| 11 | renal cell carcinoma (disease) | 99.31% | DL |
| 12 | dermatofibrosarcoma protuberans | 99.29% | DL |
| 13 | conventional fibrosarcoma | 99.28% | DL |
| 14 | low grade fibromyxoid sarcoma | 99.26% | DL |
| 15 | renal carcinoma | 99.25% | DL |
| 16 | angiolipoma | 99.25% | DL |
| 17 | collecting duct carcinoma | 99.12% | DL |
| 18 | bone fibrosarcoma | 99.04% | DL |
| 19 | renal pelvis carcinoma | 99.03% | DL |
| 20 | familial spontaneous pneumothorax | 99.00% | DL |
Showing top 20 of 51 predictions.
About TxGNN Predictions
Prediction Sources
| Source | Description |
|---|---|
| KG | Knowledge Graph - Network topology-based associations |
| DL | Deep Learning - Neural network score prediction |
Evidence Levels
| Level | Definition |
|---|---|
| L1 | Multiple Phase 3 RCTs / Systematic Reviews |
| L2 | Single RCT or multiple Phase 2 trials |
| L3 | Observational studies / Large case series |
| L4 | Preclinical / Mechanistic / Case reports |
| L5 | AI prediction only (current) |
Clinical Validation Needed
Research Use Only: These predictions are computational hypotheses that require clinical validation. They should NOT be used for clinical decision-making.
Next Steps for Validation
- Literature Review: Search PubMed for existing evidence
- Clinical Trial Search: Check ClinicalTrials.gov for ongoing studies
- Mechanistic Analysis: Evaluate biological plausibility
- Preclinical Studies: Conduct in vitro/in vivo validation
- Clinical Trials: Design and conduct human studies
Data Access
- FHIR API:
/fhir/ClinicalUseDefinition/ - CSV Download: All Predictions
- GitHub: yao-care/EuTxGNN
Citation
If using this data, please cite:
@article{huang2023txgnn,
title={A foundation model for clinician-centered drug repurposing},
author={Huang, Kexin and others},
journal={Nature Medicine},
year={2023},
doi={10.1038/s41591-023-02233-x}
}
Disclaimer: This report is for research purposes only and does not constitute medical advice. Drug repurposing predictions require rigorous clinical validation before any therapeutic application.